Leerink Partnrs Issues Negative Outlook for ELAN Earnings

Key Points

• Leerink Partners has issued a negative outlook for Elanco Animal Health, lowering their Q3 2025 earnings per share estimate from $0.14 to $0.13.
• Despite the lowered earnings forecast, Elanco Animal Health has a Strong-Buy rating from Leerink Partners and several other brokerages maintain positive ratings, with target prices ranging from $17.00 to $19.00.
• The company's recent earnings report showed a 4.8% year-over-year revenue increase, with $1.24 billion in revenue and $0.26 earnings per share, exceeding analysts' expectations.

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Research analysts at Leerink Partnrs dropped their Q3 2025 earnings per share (EPS) estimates for shares of Elanco Animal Health in a research note issued to investors on Thursday, August 7th. Leerink Partnrs analyst D. Clark now expects that the company will post earnings of $0.13 per share for the quarter, down from their prior forecast of $0.14. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health's FY2025 earnings at $0.90 EPS and FY2026 earnings at $1.00 EPS.

ELAN has been the subject of a number of other research reports. Wall Street Zen upgraded Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. William Blair upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research note on Thursday, June 26th. Stifel Nicolaus boosted their target price on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Wednesday, July 2nd. Leerink Partners upgraded Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a research note on Thursday, July 17th. Finally, Piper Sandler upped their price objective on Elanco Animal Health from $12.00 to $18.00 and gave the company a "neutral" rating in a research note on Monday. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Elanco Animal Health presently has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

Elanco Animal Health Stock Down 2.1%

ELAN stock traded down $0.38 during mid-day trading on Monday, reaching $17.44. 1,405,849 shares of the company traded hands, compared to its average volume of 5,423,075. The stock has a market cap of $8.66 billion, a price-to-earnings ratio of 20.26, a P/E/G ratio of 3.23 and a beta of 1.66. The company has a quick ratio of 1.40, a current ratio of 2.60 and a debt-to-equity ratio of 0.61. Elanco Animal Health has a fifty-two week low of $8.02 and a fifty-two week high of $17.83. The firm's 50 day moving average price is $14.56 and its 200 day moving average price is $12.19.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a return on equity of 7.04% and a net margin of 9.68%. The company's quarterly revenue was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.30 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ELAN. Allworth Financial LP grew its position in Elanco Animal Health by 791.7% in the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after acquiring an additional 2,090 shares in the last quarter. CoreCap Advisors LLC purchased a new position in Elanco Animal Health in the fourth quarter worth $29,000. NBC Securities Inc. purchased a new position in Elanco Animal Health in the first quarter worth $40,000. Parallel Advisors LLC grew its position in Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after acquiring an additional 1,852 shares in the last quarter. Finally, Versant Capital Management Inc grew its position in Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock worth $46,000 after acquiring an additional 1,740 shares in the last quarter. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.